Hoffmann-la Roche

This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab) given before and after surgery for people with early-stage non-small cell lung cancer. The goal was to see if the treatment was safe and helped shrink tumors before surgery. The study was te…

This study tested adding tiragolumab to atezolizumab in people with non-small cell lung cancer who had surgery and chemotherapy. The goal was to see if the combination worked better than atezolizumab alone. The trial was stopped early, and only 56 people took part. The main focus…

This study tested a targeted pill called pralsetinib against standard chemotherapy in people with a rare type of advanced lung cancer driven by a RET gene fusion. The goal was to see if pralsetinib could delay cancer growth better than chemo. The trial was stopped early, but resu…

This study looked at whether adding atezolizumab to cabozantinib helps people with advanced kidney cancer that got worse after immunotherapy. It included 522 adults with inoperable or spread kidney cancer. The trial was stopped early, so results are limited, but the goal was to s…